Get started
ELI LILLY COELI LILLY COELI LILLY CO

ELI LILLY CO

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

LLYC trade ideas

ELI LILLY ahead of a 1D Golden Cross targeting $1225Last time we looked at Eli Lilly (LLY) 3 months ago (November 21 2024, see chart below), we've identified the bottom of its 5-year Channel Up and issued a strong long-term buy signal: Now we are upgrading our Target as the price action turned out to be very similar to the 2nd half of 2020, at the end of which the company witnessed strong growth. As you can see both 2020 and 2024 patterns have been correction phases in the form of Channel Downs. Even their 1D RSI sequences are similar. A 1D Death Cross paved the way for the bottom soon after and a 1D Golden Cross (Jan 11 2021) confirmed the start of a new phase of growth. The price is now above the 1D MA200 (orange trend-line) and if it continues to replicate 2021, then we expect this to be a Bullish Leg that will target the 1.786 Fibonacci extension. Our long-term Target now goes from $1135 to $1225. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
LLY Technical Analysis for Feb. 7Chart Insights (Hourly Timeframe): 1. Trend Analysis: * The price shows an upward trend within a rising channel. Support levels align with the lower trendline around $827, while the upper boundary projects resistance near $880–$900. * MACD: A bearish crossover with a declining histogram suggests a possible pullback or consolidation phase. * Stochastic RSI: The oscillator is moving down from the overbought zone, signaling decreased momentum. 2. Key Support/Resistance Levels: * Support: $827, $816, $798. * Resistance: $870, $887, $900. 3. Volume: * Volume spikes align with upward movements, but the recent decline indicates waning bullish enthusiasm near resistance. Options GEX Analysis: 1. Call Walls: * Significant resistance at $887 (78.68% Call Wall) and $900 (89.5% Call Resistance / Gamma Wall). * Likely a tough level for bulls to break without substantial volume. 2. Put Walls: * Support levels at $762.5 (HVL), $750 (2nd Put Wall), and $740. 3. Market Sentiment: * GEX leaning bullish (27.6% Calls), but IV (7.7) and IVx avg (30.4) imply low implied volatility—cautioning reduced movement potential. Trading Plan Bullish Scenario: * Conditions: If LLY maintains support above $860 and breaks $870 with increased volume. * Strategy: Buy Call Option at $870 strike. Target $887–$900. * Entry: Upon a breakout above $870. * Stop Loss: Below $860. * Profit Target: $887–$900. Bearish Scenario: * Conditions: If LLY loses $860 support and stochastic RSI continues bearish. * Strategy: Buy Put Option at $850 strike. Target $827–$816. * Entry: Upon breakdown below $860. * Stop Loss: Above $870. * Profit Target: $827–$816. Disclaimer: This analysis is for educational purposes only and not financial advice. Always confirm real-time GEX updates and monitor price action during the market session. Practice proper risk management.
NYSE:LLY
by BullBearInsights
2
LLY - in preparation for strong earnings report!Moving on to our next great Stock set up - LLY Eli Lilly and Company (LLY) has demonstrated robust financial performance, driven by its innovative pharmaceutical offerings, particularly in the weight-loss segment. In the third quarter of 2024, the company reported a 20% year-over-year increase in revenue, totaling $11.44 billion. This growth was primarily attributed to a 15% rise in sales volume and a 6% increase in realized prices. Key contributors to this success were the weight-loss drugs Mounjaro and Zepbound. Looking ahead, analysts are optimistic about Eli Lilly's financial trajectory. The company is expected to report fourth-quarter 2024 revenue of approximately $13.5 billion, marking a 45% increase compared to the same period in the previous year. This projection includes significant contributions from Mounjaro and Zepbound, with anticipated revenues of $3.5 billion and $1.9 billion, respectively. Analysts have expressed positive sentiments, with 10 out of 11 surveyed by Visible Alpha rating the stock as a "buy" and setting an average price target of nearly $986, approximately 21% higher than current levels. Overall, Eli Lilly's strategic focus on innovative treatments and its strong product pipeline have positioned the company for continued financial success. So far we believe that the strong fundamentals , and current growth provided by the weight loss drug that has had tremendeous success we would see a positive outcome on their earnigns and growth potetial. Entry: 813 Target 1: 857 - 1st weak resistance Target 2:950 - 2nd strong resistance SL: 750 around the strong support area
NYSE:LLYLong
by DG55Capital
5
LLY Technical Analysis & Options Trading Insights - Hot on RadarPrice Action Overview LLY continues to show strength with a clear upward trajectory. The stock is trending within a rising channel on the hourly timeframe, supported by increased volume. It recently tested the upper boundary of the channel around $825 and showed resilience, suggesting strong bullish sentiment. MACD and Stochastic RSI indicate overbought conditions, signaling caution for new buyers at current levels. Support and Resistance Levels * Immediate Resistance: $830 (recent high and near the 2nd CALL Wall on GEX) * Key Support Levels: * $814 (channel mid-line and prior consolidation area) * $800 (psychological level) * $774 (HVL support level from GEX) Options GEX Analysis * Highest Positive NETGEX/Call Wall: $830 * 2nd CALL Wall: $825 (current area of interest) * PUT Walls: * $720 (significant put support) * $700 (third support level with strong gamma influence) Trading Plan 1. Bullish Scenario: * Entry: Near $814 (pullback to mid-channel support) or $825 (breakout above resistance). * Target: $830 and then $840 (measured move based on channel projection). * Stop-Loss: Below $810 to mitigate downside risk. 2. Bearish Scenario: * Entry: If the price fails to hold $814 and breaks below $810. * Target: $800 and $774. * Stop-Loss: Above $818 to control losses in a false breakdown. Options Trading Suggestions * Bullish Setup: * Buy Call: Strike $820, Expiry 2-3 weeks out. * Spread: Bull Call Spread $820/$830 to reduce risk. * Bearish Setup: * Buy Put: Strike $810, Expiry 2-3 weeks out. * Spread: Bear Put Spread $810/$800. Thoughts on Direction The strong trend and bullish momentum suggest further upside if LLY maintains its current channel. A breakout above $830 could accelerate the move to $840 or higher. However, watch for overbought signals in the short term and consider profit-taking if resistance holds. Disclaimer This analysis is for educational purposes only and does not constitute financial advice. Price levels and market conditions may change in premarket or during trading hours. Adjust trading strategies accordingly, and for specific questions, feel free to reach out. Always conduct your own due diligence and manage risks responsibly.
NYSE:LLY
by BullBearInsights
LLY to follow NVO ? A bearish Head & Shoulders in NYSE:LLY weekly chart (as well in daily chart). NYSE:LLY last move is stuck under a downtrend line (in white) which forms the right shoulder. In addition, the head part forms another bearish pattern - a double top. If the head & shoulders forms is applied, NYSE:LLY may go down to its support level at $433. The entire healthcare sector looks bad at the moment and NYSE:LLY 's rival NYSE:NVO has already formed and applied a head and shoulders pattern. Will NYSE:LLY follow NYSE:NVO ? time will tell but the writing is on the wall.
NYSE:LLYShort
by ravivhe94
Loss in weight loss Drugs GLP1 Drug producers started 2024 with very strong momentum with Lilly touching nearly a market cap of 1T USD. But since then, the GLP1 manufactures have lost a lot of momentum. Novo Nordisk is at 52 weeks low as shown by the red line. Eli Lilly stock chart also showing bearish engulfing candle. The 20-Day, 50-Day and 100-Day are almost below the 200 Day SMA showing bearish divergence. IN the short to medium term the Price trend looks bearish unless there is a positive catalyst for the stock.
NYSE:LLYShort
by RabishankarBiswal
3
LLY: Bearish Trend and Short-term Risk🔥 LucanInvstor's Strategy: 🩸 Short: Below $738.05, targeting $720 and $700. The MACD remains negative, and the price is below both the 9-day and 200-day EMAs, signaling a continued downtrend in the short term. 🩸 Long: Above $824.17, targeting $830 and $850. A break above resistance could resume the bullish trend, but caution is needed due to current bearish pressures. 🔥 LucanInvstor's Commands: 🩸 Resistance: $824.17 — A key resistance level; breaking above this could trigger further upside. 🩸 Support: $738.05 — A critical support level; a breakdown below this could lead to further declines. Eli Lilly is under bearish pressure in the short term, with increasing selling volume and negative MACD momentum. A breakdown below support could lead to a further pullback, while a breakout above resistance could signal a reversal of the current trend. 👑 "In the face of adversity, clarity in action drives success."
NYSE:LLY
by LucanInvestor
1
symmetri triangel Eli Lilly has formed a symmetrical triangle after falling from an ascending trend. The hypothesis is supported by decreasing volume towards the apex. Ideally, the breakout should occur 2/3 of the way into the triangle. That is not the case here. Now we are close to the apex, so a breakout must be imminent. It is difficult to predict the direction of the breakout with a symmetrical triangle, even though the upper boundary has been tested the most. Be mindful of false breakouts – a true breakout should occur with high volume. Disclaimer: I have a position in Eli Lilly.
NYSE:LLY
by scorpiris
1
Halftime Report: LLY Up From Here? Hold for better PriceWe've been watching LLY after Open this morning allowed it to bounce up to $783.63. It has since settled on the 50% Retracement on the 5 Minute, which we were looking for it to break down back to at least the $765-$766 Price Range, looking to get in around $765.45specifically. With a Price Target $775 (Short-Term Trade Target) on the rebound and retest. We're looking at a stop around $761.97 to be safe in case it comes down hard and surpasses our entry. On a longer-time frame, we're looking for potential a $780.65 - $785 retest. Stay tuned by connecting at the website in our signature! We deliver this and more financial tools to make life that much easier on You! - @MyMIWallet #MyMIWallet
NYSE:LLYLong
by MyMIWallet
LLY 1H Swing Long Aggressive Trend TradeAggressive Trend Trade - short impulse + volumed TE / T1 + support level + biggest volume Sp + weak test + first bullish bar close entry Calculated affordable stop limit 1 to 2 R/R take profit Daily Context "+ long impulse + 1/2 correction - expanding T2 + support level + volumed manipulation" Monthly Context "+ long impulse + 1/2 correction + T2 level + support level - biggest volume manipulation" Yearly Context "+ long impulse - neutral zone"
NYSE:LLYLong
by MishaSuvorov
Why Buy LLY?A textbook spike trade... that's why! Every morning the stock market open gives us opening volatility spikes on the first 30 minute bar. Most are noise but when that rare one comes along that fits my rules AND has multiple matching confluences... it's time to "Strike at the Spike!" This setup has going for it: At a 50% Retracement of the recent trend (from November 18 - December 4) At the top of a Gap Level At the Volume Profile Point-of-Control for the last year of price action (see below) With a Spike that my indicator shows >80% ATR Clearance I consider the baseline for a trade; this one is 150% so it definitely fits the rules. I would take a spike if there were only 2 of those matching levels above. Targeting the local high for the first take profit at 834. Here is the Daily chart for just how key this level is: Full disclosure: NYSE:LLY is and has been one of my biggest holdings; having owned the stock for over a decade.
NYSE:LLYLong
by norok
Eli Lilly: Is the Uptrend Fading?Eli Lilly has been one of the best-performing large-cap stocks in recent years. But now it may be showing signs of stalling. The first pattern on today’s chart is the bearish price gap on October 30 after earnings and revenue missed estimates. LLY has remained below the gap since, which may suggest that new resistance has been established. Second, the recent bounce pulled stochastics into overbought territory. Third, the drugmaker has remained below its 200-day simple moving average (SMA). The 50-day SMA is also nearing a potential “death cross” below its 200-day SMA. Finally, consider that LLY is up 578 percent in the five-year period ended last month. That’s the fourth-biggest gain in the S&P 500 over the period, according to TradeStation Data. (Nvidia, Tesla and Builders FirstSource have risen more.) Given the magnitude of its run, many investors could be sitting on significant long-term gains. Could that open the door to profit taking? TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NYSE:LLY
by TradeStation
2
Can Pharma Innovation Rewrite Healthcare's Future?In the rapidly evolving landscape of medical technology, Eli Lilly emerges as a beacon of transformative potential, challenging conventional boundaries of pharmaceutical innovation. With a strategic masterstroke, the company has positioned itself at the forefront of medical breakthroughs, particularly in the revolutionary realm of weight loss and diabetes treatments. The remarkable Zepbound medication stands as a testament to this vision, demonstrating unprecedented efficacy by enabling patients to lose an average of 20.2% body weight - a figure that not only surpasses competitors but also represents a paradigm shift in medical intervention. The company's financial architecture is equally compelling, reflecting a meticulously crafted approach to growth and shareholder value. With a staggering market capitalization of $722 billion, a 27.4% revenue growth, and an impressive 80.9% gross profit margin, Eli Lilly transcends the traditional pharmaceutical business model. Its recent $15 billion share buyback program and consistent 54-year dividend payment history underscore a strategic philosophy that balances aggressive innovation with prudent financial management, creating a blueprint for sustainable corporate success. Beyond financial metrics and breakthrough medications, Eli Lilly represents something more profound: a vision of healthcare's future where technology, research, and human potential converge. The company's $3 billion manufacturing expansion, commitment to oncology research with drugs like Jaypirca, and continuous investment in cutting-edge medical solutions paint a picture of an organization that sees beyond immediate profit - an entity committed to reshaping human health through relentless innovation and scientific excellence. In an era of unprecedented medical challenges, Eli Lilly stands not just as a pharmaceutical company, but as a harbinger of hope, demonstrating how visionary thinking can transform global health landscapes.
NYSE:LLYLong
by signalmastermind
Eli Lilly is facing problems after the earnings presentation🔴 Eli Lilly is facing problems after the earnings presentation NYSE:LLY has broken an especially important support and is now in free fall. Avoid buying it now. The break also activates the bearish double top and that means that the $550 is the target of the pattern. If you look close to the chart, the volume appears in the $550-600 area, which is very similar to the double top target price. $725 is the last support before a free fall to under $600.
NYSE:LLYShort
by TopChartPatterns